Vol. 13. Núm. 9.
Páginas 497-502 (Mayo 2020)

Actualización
Patología inflamatoria y autoinmune de la vía biliar

Inflammatory and autoimmune disease of the bile duct

N. Vallejo SenraJ.E. Domínguez-Muñoz
Doi : https://10.1016/j.med.2020.05.021
Opciones
Resumen

La patología inflamatoria de la vía biliar hace referencia a un grupo de enfermedades de tipo inflamatorio que afecta a la vía biliar intra y/o extrahepática. La patogenia de estas enfermedades es variable, dependiendo del tipo de enfermedad y estructuras afectas. Los orígenes pueden ser desde una litiasis enclavada hasta una reacción inflamatoria autoinmune. Las manifestaciones clínicas también variarán según la naturaleza de la enfermedad, siendo lo más habitual que se presente dolor en hipocondrio derecho e ictericia, aunque pueden abarcar desde un paciente asintomático con hallazgos analíticos a un paciente con fallo hepático. Los pilares diagnósticos de este tipo de enfermedades son la clínica, las pruebas analíticas y las técnicas de imagen. En ocasiones será necesario también la histología mediante biopsia hepática u otras técnicas. El tratamiento puede variar según el tipo de enfermedad y los síntomas del paciente, abarcando desde el manejo sintomático y el drenaje endoscópico de la vía biliar hasta la cirugía.

Palabras clave
Colangitis
Colecistitis
Autoinmunidad
Vía biliar
Abstract

Inflammatory bile duct disease refers to a group of inflammatory diseases that affect the intrahepatic and extrahepatic bile duct. The pathogenesis of these diseases varies depending on the type of disease and affected structures. The origins can range from an embedded lithiasis to an autoimmune inflammatory reaction. The clinical manifestations also vary according to the nature of the disease, and the most common are pain in the right hypochondrium and jaundice, although the presentation can extend from no symptoms with suggestive laboratory findings to hepatic failure. The diagnostic bases for this type of disease are its symptoms, laboratory tests and imaging techniques. Occasionally, histology through liver biopsy or other techniques might be necessary. The treatment can vary depending on the type of disease and symptoms, encompassing the management of symptoms, endoscopic drainage of the bile duct and surgery.

Keywords
Cholangitis
Cholecystitis
Autoimmunity
Bile duct

Identifíquese

¿Aún no es suscriptor de la revista?

Comprar el acceso al artículo

Comprando el artículo el pdf del mismo podrá ser descargado

Teléfono para incidencias

De lunes a viernes de 9h a 18h (GMT+1) excepto los meses de julio y agosto que será de 9 a 15h

Llamadas desde España 932 415 960
Llamadas desde fuera de España +34 932 415 960
Bibliografía
[1]
202006080629562601
202006080629562602
European Association for the Study of the Liver.
EASL Clinical practice guidelines: the diagnosis and management of patients with primary biliary colangitis.
J Hepatol., (2017), 67 pp. 145-172
[2]
C.O.
202006080629562603
Zein, P. Angulo, K.D. Lindor.
When is liver biopsy needed in the diagnosis of primary biliary cirrhosis?.
Clin Gastroenterol Hepatol., (2003), 1 pp. 89-95
[3]
B.G.
202006080629562604
Taal, S.W. Schalm, A.M. de Bruyn, A.M. de Bruyn, F.W. de Rooy, F. Klein.
Serum IgM in primary biliary cirrhosis.
Clin Chim Acta., (1980), 108 pp. 457-463
[4]
G.M.
202006080629562605
Hirschfield.
Diagnosis of primary biliary cirrhosis.
Best Pract Res Clin Gastroenterol., (2011), 25 pp. 701-712
[5]
G.M.
202006080629562606
202006080629562607
Hirschfield, J.K. Dyson, G.J.M. Alexander, et al.
The British Society of Gastroenterology/UK – PBC primary biliary colangitis treatment and management guidelines.
Gut., (2018), 67 pp. 1588-1594
[6]
Y.
202006080629562608
Bacq, L. Sentilhes, H.B. Reyes, A. Glantz, J. Kondrackiene, T. Binder, et al.
Efficacy of ursodeoxycholic acid in treating intrahepatic cholestasis of pregnancy: a meta-analysis.
Gastroenterology., (2012), 143 pp. 1492-1501
[7]
F.
202006080629562609
2020060806295626010
Nevens, P. Andreone, G. Mazzella, Strasser SI1, Bowlus C1, P. Invernizzi, et al.
A placebo-controlled trial of obeticholic acid in primary biliary cholangitis.
N Engl J Med., (2016), 375 pp. 631-643
[8]
K.
2020060806295626011
Hosonuma, K. Sato, Y. Yamazaki, M. Yanagisawa, H. Hashizume, N. Horiguchi, et al.
A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia.
Am J Gastroenterol., (2015), 110 pp. 423-431
[9]
J.
2020060806295626012
Ludwig.
Small-duct primary sclerosing cholangitis.
Semin Liver Dis., (1991), 11 pp. 11-17
[10]
M.H.
2020060806295626013
2020060806295626014
Chapman, D. Thorburn, G.M. Hirschfield, G.G.J. Webster, S.M. Rushbrook, G. Alexander, et al.
British Society of Gastroenterology and UK – PSC guidelines for the diagnosis and management of primary sclerosing cholangitis.
Gut., (2019), 68 pp. 1356-1378
[11]
K.D.
2020060806295626015
Lindor, K.V. Kowdley, M.E. Harrison.
American College of Gastroenterology. ACG Clinical guideline: primary sclerosing cholangitis.
Am J Gastroenterol., (2015), 110 pp. 646-659
[12]
W.R.
2020060806295626016
Kim, T.M. Therneau, R.H. Wiesner, J.J. Poterucha, J.T. Benson, M. Malinchoc, et al.
A revised natural history model for primary sclerosing cholangitis.
Mayo Clin Proc., (2000), 75 pp. 688-694
[13]
P.
2020060806295626017
Angulo, D.H. Pearce, C.D. Johnson, J.J. Henry, N.F. LaRusso, B.T. Petersen, et al.
Magnetic resonance cholangiography in patients with biliary disease: its role in primary sclerosing cholangitis.
[14]
P. Tandon, B.H. Rowe, B. Vandermeer, V.G. Bain.
The efficacy and safety of bile acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus.
Am J Gastroenterol., (2007), 102 pp. 1528-1536
[15]
D.C.
2020060806295626018
Buckles, K.D. Lindor, N.F. Larusso, L.M. Petrovic, G.J. Gores.
In primary sclerosing cholangitis, gallbladder polyps are frequently malignant.
Am J Gastroenterol., (2002), 97 pp. 1138-1142
[16]
C.K.
2020060806295626019
Triantos, N.M. Koukias, V.N. Nikolopoulou, A.K. Burroughs.
Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis.
Aliment Pharmacol Ther., (2011), 34 pp. 901-910
[17]
M.C.
2020060806295626020
Allison, J.A. Sandoe, R. Tighe, I.A. Simpson, R.J. Hall, T.S. Elliott.
Endoscopy Committee of the British Society of Gastroenterology. Antibiotic prophylaxis in gastrointestinal endoscopy.
Gut., (2009), 58 pp. 869-880
[18]
H.
2020060806295626021
Umehara, K. Okazaki, Y. Masaki, M. Kawano, M. Yamamoto, T. Saeki, et al.
Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011.
Mod Rheumatol., (2012), 22 pp. 21-30
[19]
A.
2020060806295626022
2020060806295626023
Tanaka, S. Tazuma, K. Okazaki, T. Nakazawa, K. Inui, T. Chiba, et al.
Clinical features, response to treatment, and outcomes of IgG4-related sclerosing cholangitis.
Clin Gastroenterol Hepatol., (2017), 15
[20]
H.
2020060806295626024
Ohara, K. Okazaki, H. Tsubouchi, et al.
Clinical diagnostic criteria of IgG4-related sclerosing cholangitis.
2012. J Hepatobiliary Pancreat Sci., (2012), 19 pp. 536-542
[21]
M.T.
2020060806295626025
Huggett, E.L. Culver, M. Kumar, J.M. Hurst, M. Rodríguez-Justo, M.H. Chapman, et al.
Type 1 autoimmune pancreatitis and IgG4-related sclerosing cholangitis is associated with extrapancreatic organ failure, malignancy, and mortality in a prospective UK cohort.
Am J Gastroenterol., (2014), 109 pp. 1675-1683
[22]
A.
2020060806295626026
2020060806295626027
Tanaka.
Inmunoglobulin G4-related esclerosing colangitis.
J Dig Dis., (2019), 20 pp. 357-362